NCT06899854Recruiting
Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer.
Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer Undergoing Systemic Therapy, Surgical Resection, or Liver Biopsy.
Source: ClinicalTrials.gov · Last updated 3 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The project aims to collect blood, tissue samples, and clinical data from patients with primary liver cancer (mainly hepatocellular carcinoma and intrahepatic cholangiocarcinoma) undergoing systemic therapy, surgical resection, or liver biopsy. Primary liver cancer is a growing global health challenge, with over one million cases expected by 2025 and a lack of effective treatments. The three-year study will systematically collect and store samples to support translational research for new therapies. Blood will be drawn at key points during systemic therapy, while tissue samples will be obtained from surgical resections or biopsies, provided they are not needed for diagnostics.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 53 (estimated)
- First submitted
- 21 Mar 2025
- Start date
- 19 Jun 2023
- Primary completion date
- 19 Mar 2025
- Lead sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06899854
What you commit to
- Study type: Observational
- Planned participants: 53
- From 19 Jun 2023 to the primary completion date, 19 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent conditions with a life expectancy of less than 12 months
- Tumors resected with curative intent and with no evidence of disease recurrence for \>3 years prior to signing the informed consent, considered at low risk of recurrence
Other illness
- Autoimmune or chronic inflammatory diseases
- Other active extrahepatic malignancies or those treated within the last 3 years, except for the following exceptions:
- Adequately resected non-melanoma skin cancers or lentigo maligna with no evidence of metastasis
- Prostatic intraepithelial neoplasia with no evidence of infiltrative disease
- HIV infection
- Lack of patient cooperation or failure to sign the informed consent
Other
- Substance abuse dependency
- Adequately treated carcinoma in situ of the cervix with no evidence of recurrence
- Adequately treated non-invasive papillary urothelial tumors or urothelial carcinoma in situ
Who the study is looking for
- Primary liver cancer (hepatocellular carcinoma or intrahepatic cholangiocarcinoma)
- Signed informed consent
- Patient eligible to start first-line systemic therapy
- Patient eligible for surgical resection
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fondazione IRCCS Policlinico San Matteo di Pavia Coordinator of this site? Confirm its status | Pavia | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.